Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.37 |
| ▸ | C1S | P09871 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302106 | 0.84 | NPC1 (0.33) | NPC1RAB9AALDH1A1ALOX15 | |
| SCHEMBL6808928 | 0.80 | F2 (0.41) | NPC1RAB9AF2F10F12 | |
| SCHEMBL2171273 | 0.80 | NPC1 (0.60) | NPC1RAB9ABLMRECQLKMT2A | |
| SCHEMBL11594420 | 0.80 | NPC1 (0.60) | NPC1RAB9ABLMRECQLKMT2A | |
| SCHEMBL4634722 | 0.78 | NPC1 (0.32) | NPC1RAB9AALDH1A1ALOX15 | |
| SCHEMBL11229875 | 0.78 | TSHR (0.41) | NPC1RAB9AF2F10F12 | |
| SCHEMBL4684957 | 0.77 | NPC1 (0.38) | NPC1RAB9AF2F10ALDH1A1 | |
| SCHEMBL896901 | 0.76 | NPC1 (0.41) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL10495281 | 0.75 | F2 (0.55) | F2F10F12F7F3 | |
| SCHEMBL9045774 | 0.75 | GAA (0.46) | NPC1RAB9AKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | claimed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | claimed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | claimed |
| US-20040014994-A1 | Method for resolving chiral (2s) and (2r) chromanes | ELI LILLY AND COMPANY | 2004-01-22 | — | — | US | disclosed |
| EP-1292588-A1 | METHODS FOR RESOLVING CHIRAL (2S) AND (2R) CHROMANES | Eli Lilly & Company (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1286982-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYLIC COMPOUNDS AND CHIRAL BNEZOPYRAN DERIVATIVES | Eli Lilly & Company (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094333-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYCLIC COMPOUNDS AND CHIRAL BENZOPYRAN DERIVATIVES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001094334-A1 | METHODS FOR RESOLVING CHIRAL (2S) AND (2R) CHROMANES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014994-A1 | Method for resolving chiral (2s) and (2r) chromanes | TBXA2R, TBXAS1, SRR | NPC1 4667/4885RAB9A 1587/4885F2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.